Evaluating only NeuralStem’s profile at its peak — without knowing the outcome — the model ranked Founder chaos as the #1 likely cause. Documented cause: Product failure.
Key Events Timeline
FOUNDING
NeuralStem founded in Rockville, MD; pioneers isolation and commercialization of human neural stem cells.
PRODUCT LAUNCH
NSI-189 Phase 2 for major depressive disorder fails primary endpoint; stock falls 60% in single session.
DOWN ROUND
NeuralStem raises $8M at heavily diluted terms; ALS program NSI-566 Phase 2 shows no meaningful functional improvement.
BANKRUPTCY
NeuralStem files Chapter 7 bankruptcy with $2.1M cash remaining and no active clinical programs.
Full Analysis
Free · no account needed
Documented cause
NeuralStem, a 25-year-old Nasdaq-listed CNS stem cell therapy pioneer, filed Chapter 7 bankruptcy in June 2021 after decades of clinical frustration. Its neural stem cell therapy NSI-566 for ALS showed no statistical benefit in Phase 2, and spinal cord injury program NSI-189 for major depression failed Phase 2 in 2017. CEO Richard Garr had kept the company alive through continuous dilutive financings but by 2021 had only $2.1M cash remaining with no viable clinical programs.
Lesson
“Serial dilutive financing without clinical progress destroys shareholder value; know when to stop.”